Crossmark

Reply to: Technical challenges of studying the impact of plasma components on the efficacy of lipid nanoparticles for vaccine and therapeutic applications

Crossref DOI link: https://doi.org/10.1038/s41467-024-47726-2

Published Online: 2024-05-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Kai https://orcid.org/0000-0002-3045-0809
Lázaro-Ibáñez, Elisa https://orcid.org/0000-0002-3542-7069
Lerche, Michael

Lindén, Daniel https://orcid.org/0000-0003-4158-8018
Salvati, Anna https://orcid.org/0000-0002-9339-0161
Sabirsh, Alan https://orcid.org/0000-0001-5310-0281
License Information

Text and Data Mining valid from 2024-05-09

Version of Record valid from 2024-05-09
More Information

Article History

Received: 24 October 2023

Accepted: 10 April 2024

First Online: 9 May 2024

Competing interests

: Kai Liu, Elisa Lázaro-Ibáñez, Michael Lerche, Daniel Lindén and Alan Sabirsh are or were at the time of work employees of AstraZeneca. Anna Salvati declares no competing interests.

Document is current

Any future updates will be listed below